These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381 [No Abstract] [Full Text] [Related]
5. ARBs for cardiovascular and renal protection in high-risk patients. Aalbers J Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697 [No Abstract] [Full Text] [Related]
6. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study]. Burnier M; Waeber B; Hess O; Lüscher T Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371 [No Abstract] [Full Text] [Related]
7. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading? Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085 [No Abstract] [Full Text] [Related]
9. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure. Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357 [No Abstract] [Full Text] [Related]
10. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes]. Middeke M Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983 [No Abstract] [Full Text] [Related]
11. [Therapy of hypertension. Lasting organ protection moves into the foreground]. MMW Fortschr Med; 2003 Nov; 145(47):62. PubMed ID: 14738040 [No Abstract] [Full Text] [Related]
12. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both? Neldam S Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992 [TBL] [Abstract][Full Text] [Related]
13. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction]. Nilsson PM Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975 [No Abstract] [Full Text] [Related]
14. [Telmisartan (micardis) -- an antagonist of angiotensin 2 of type 1 receptors: another antihypertensive drug or something greater?]. Chazova IE Ter Arkh; 2003; 75(6):89-91. PubMed ID: 12920969 [No Abstract] [Full Text] [Related]
15. [Therapy of hypertension. Also pulse pressure must be reduced]. MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584451 [No Abstract] [Full Text] [Related]
16. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?]. MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331 [No Abstract] [Full Text] [Related]
17. Nondipping and cardiovascular risk after morning renin-angiotensin blockade. Portaluppi F; Smolensky M; Ayala DE; Hermida RC Hypertension; 2013 Feb; 61(2):e15. PubMed ID: 23248148 [No Abstract] [Full Text] [Related]
18. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. Mancia G; Unger T; Zanchetti A J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549 [No Abstract] [Full Text] [Related]
19. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study. Sharma A; Baliga V; J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142 [TBL] [Abstract][Full Text] [Related]
20. Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies. Gosse P; Schumacher H Hypertens Res; 2014 Feb; 37(2):151-7. PubMed ID: 24048485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]